Manages central (cranial) diabetes insipidus. ANDA 215961, held by Dr. Reddy's Laboratories. Desmopressin Acetate.
As of Nov 21, 2026, ANDA 215961 (Desmopressin Acetate), held by Dr. Reddy's Laboratories, was first approved by FDA on Aug 19, 2022, with 0 approved supplements and 0 published complete response letters.
Desmopressin Acetate Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desmopressin Acetate0.004MG/ML · injectable;injection | Desmopressin Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters